For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Point-of-care testing (POCT) may be defined as the rapid specific testing of bodily fluids at the bedside.
Owing to the relatively long turnaround time of conventional laboratory tests, and with the aim of reducing inappropriate transfusion, there is increasing interest in point-of-care coagulation testing (POCCT) which can provide results within minutes. In addition, the wide acceptance of the current cell-based model of coagulation has led to an emphasis on the pivotal role of platelets and particular interest in devices testing whole blood, rather than plasma used in laboratory-based tests. The latter include the prothrombin time (PT) and activated partial thromboplastin time (aPTT) which provide information on the first phase of coagulation up to fibrin formation. Conversely, viscoelastic POCCT devices produce information on all phases of coagulation, providing insight into interactions between the cellular and plasma components of whole blood and the activity of the fibrinolytic system; all of which are vital for successful haemostasis.
The Point-Of-Care Coagulation Testing Devices market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Point-Of-Care Coagulation Testing Devices industry, and breaks down according to the type, application, and consumption area of Point-Of-Care Coagulation Testing Devices. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Point-Of-Care Coagulation Testing Devices in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Point-Of-Care Coagulation Testing Devices market covered in Chapter 11:
Medtronic
Siemens Healthcare GmbH
Helena Laboratories
Abbott
Hoffmann-La Roche Ltd.
Accriva Diagnostics
Werfen
Sysmex Corporation
Danaher
In Chapter 3, on the basis of types, the Point-Of-Care Coagulation Testing Devices market from 2018 to 2028 is primarily split into:
Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices
Bleeding Time Testing Devices
Fibrinogen Level Testing Devices
Others
In Chapter 4, on the basis of applications, the Point-Of-Care Coagulation Testing Devices market from 2018 to 2028 covers:
Hospitals
Clinics
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028